Brief: TOT Biopharm International Co Posts FY Loss Attributable RMB49.9 Mln VS Loss RMB261.2 Mln
23/03/2023 15:02
March 23 (Reuters) - TOT BIOPHARM International Co Ltd
1875.HK :
* FY LOSS ATTRIBUTABLE RMB49.9 MILLION VERSUS LOSS RMB261.2
MILLION
* FY REVENUE RMB442.2 MILLION VERSUS RMB76.3 MILLION
Source text for Eikon: ID:nHKS6qdmlR
Further company coverage: 1875.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29